News / Taiwan / cnyes
TCI Gene (6677-TW) Partners with South Korean Firm to Tap $100M Prostate Drug Market
Health Technology · Pharmaceuticals: Major · cnyes · 2026-09-17
6677
Taiwan-based TCI Gene has signed an exclusive licensing agreement with South Korea's YS to market its prostate enlargement treatment, aiming to capture a share of the $100 million local market.
What Happened
Strategic Licensing: TCI Gene has entered into an exclusive licensing agreement with South Korean pharmaceutical company YS to develop and market its prostate enlargement treatment, 'Yilishu,' in Korea. This partnership is designed to penetrate the local market, which is valued at approximately $100 million.
Market Dynamics: The Korean market for this specific drug class is currently dominated by original brand-name manufacturers, who hold a 30% market share due to the high technical barriers associated with oral dissolving tablets. By teaming up with a local partner, TCI Gene aims to challenge this dominance and gain a foothold in the region.
Financial Performance: TCI Gene reported strong August revenue of NT$91.86 million, a 46.36% year-over-year increase, driven by robust sales of psychiatric medications and other key products. The company has maintained monthly revenue above NT$90 million for three consecutive months, with year-to-date revenue reaching a record high of NT$642 million.
Growth Outlook: Management remains cautiously optimistic about the second half of the year, citing optimized product portfolios and successful international expansion. With several drug certifications entering the harvest phase and stable demand for its core products, the company expects a clear growth trajectory for the coming quarter.